



## Global Access Program

Providing innovative diagnostics solutions to those **who need it most**



**Universal access to quality healthcare and medical innovation remains a global challenge.**

As a community we have an ambitious goal: to stop as many diseases as possible.

Roche continues to partner with national governments, local healthcare facilities, communities and international agencies to go beyond providing diagnostics tests.




**PEPFAR**  
U.S. President's Emergency Plan for AIDS Relief

 **The Global Fund**


The Roche Global Access Program provides access to diagnostics for HIV, hepatitis, tuberculosis and cervical cancer in high disease burden and qualified countries where reliable diagnostic solutions are needed most.



## Global Access Program Timeline




DISEASE PREVALENCE: DEATHS




DISEASE ELIMINATION GOALS


## HIV goals by 2030<sup>5</sup>




## Hepatitis goals by 2030<sup>6</sup>




## TB goals by 2030<sup>7</sup>



## Cervical cancer goals by 2030<sup>8</sup>




## COVID-19 Elimination Strategy<sup>7</sup>



COUNTRIES WITH GLOBAL ACCESS PROGRAM

The program provides increased access to diagnostics at affordable pricing for qualifying organizations in 82 eligible countries with the highest disease burden.



REFERENCES:

- <https://www.who.int/news-room/fact-sheets/detail/hiv-aids> (accessed 7 Nov 2019)
- <https://www.who.int/news-room/fact-sheets/detail/hepatitis-b> and <https://www.who.int/news-room/fact-sheets/detail/hepatitis-c> (accessed 7 Nov 2019)
- <https://www.who.int/news-room/fact-sheets/detail/tuberculosis> (accessed 7 Nov 2019)
- <https://www.who.int/news-room/press-releases/2019/11/06/who-launches-new-cervical-cancer-elimination-draft-strategy> (accessed 7 Nov 2019)
- Understanding Fast-Track. Accelerating Action to end the AIDS epidemic by 2030.
- <https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf;jsessionid=AC1645C173756FB7A161689347064065?sequence=1> (accessed 7 Nov 2019)
- The End TB Strategy 2015. Geneva: World Health Organization; 2015. WHO/HTM/TB/2015.19
- <https://www.who.int/docs/default-source/documents/cervical-cancer-elimination-draft-strategy.pdf> (accessed 7 Nov 2019)
- <https://www.who.int/data/stories/the-true-death-toll-of-covid-19-estimating-global-excess-mortality>. Accessed 28 June 2021
- Baker MG, Wilson N, Anglemeyer A. Successful Elimination of Covid-19 Transmission in New Zealand. N Engl J Med 2020;383:e56. 10.1056/NEJMc2025203

Roche Molecular Systems  
4300 Hacienda Drive  
Pleasanton, CA 94588 USA

<https://go.roche.com/Global-Access-Program>